LDC and JT team up for the discovery of new therapies

12-Oct-2023
Computer-generated image

Symbolic image

The Lead Discovery Center GmbH (LDC) and Japan Tobacco Inc. (JT) have closed a collaboration agreement to discover new first-in-class therapeutic approaches, focusing around novel chemical entities for the treatment of various diseases with significant unmet medical need.

Over a period of up to seven years, LDC, together with its extensive academic network, will identify high-potential projects that fit JT’s therapeutic priorities and in-licensing needs. The network includes research institutes of the Max Planck Society, other research organizations, as well as high-profile universities from all over Germany and beyond. Ideas for new therapeutic approaches will be collaboratively incubated at LDC as usual, although with additional support and expertise from JT. After achieving the proof-of-concept milestone by demonstrating in vivo efficacy for representatives of the respective new compound class, such projects will be targets for in-licensing by JT, where they will be further developed.

“We are pleased to team up with the LDC and its excellent network of academic inventors. The collaboration will enable us to identify truly novel therapeutic approaches that could make a meaningful difference in the lives of patients around the world”, says Muneaki Fujimoto, President of JT’s Pharmaceutical Business.

“We are excited to have a new industry partner on board who shares our brave ambition and the associated risks to transfer highly innovative approaches from academic research into application”, Bert Klebl, CEO and CSO of LDC, continues. “With their proven expertise in business and drug development, JT is perfectly positioned to advance early-stage projects along the value chain, and ultimately towards patients who urgently need new therapeutic options. We are looking forward to a productive and exciting collaboration.”

Academic inventors and their institutions will not only benefit from the drug discovery and development experience of both LDC and JT, but also from future commercialization revenues.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances